Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10874734-B2
Publication Date
2020-12-29
Expiration Date
Abstract
The present invention relates to a vaccine composition for prevention or treatment of chicken pox or herpes zoster, the vaccine composition comprising a surface protein (gE) of Varicella Zoster Virus and especially an aluminum salt as an adjuvant. The vaccine composition according to the present invention employs a protein antigen, thus showing greater outstanding stability than a live vaccine and has an optimized mixture ratio of adjuvants to elicit effective antibody induction, thereby being useful as a vaccine for preventing or treating Varicella Zoster Virus-caused chicken pox or herpes zoster.
Core Innovation
A vaccine composition is described for preventing or treating varicella or herpes zoster comprising a surface protein gE of Varicella zoster virus having the amino acid sequence set forth in SEQ ID NO: 1 and an aluminum salt as active ingredients. The composition is presented as a vaccine using a purified surface protein gE combined with an aluminum salt adjuvant.
The disclosure emphasizes that the aluminum salt formulation is used as an adjuvant in a gE protein vaccine composition, and that the specified gE:Al3+ weight ratio is immune-optimal. Aluminum salt types include aluminum hydroxide and aluminum phosphate as adjuvant options within the vaccine composition.
The invention reports immunogenicity outcomes using antibody response assessments, including ELISA titers, PRNT neutralizing titers, and FAMA binding. The described comparisons indicate higher antibody responses than a live attenuated VZV vaccine.
Claims Coverage
The document contains one independent claim, with dependent claims refining the aluminum salt subtype and optional immune enhancement components, and adding quantitative constraints. The independent claim centers on the vaccine composition defined by the gE surface protein sequence, the aluminum salt adjuvant, and a specified gE:Al3+ weight ratio range.
Vaccine composition with VZV gE SEQ ID NO: 1 and aluminum salt adjuvant
A vaccine composition for preventing or treating varicella or herpes zoster comprising a surface protein gE of Varicella zoster virus having the amino acid sequence set forth in SEQ ID NO: 1 and an aluminum salt as active ingredients.
Specified gE-to-aluminum cation weight ratio range
The content ration of the surface protein gE to aluminum cation (Al3+) in the composition is 9:1000 to 22:1000 (weight ratio).
Across the independent claim, the core inventive coverage is directed to a VZV gE (SEQ ID NO: 1) vaccine composition using an aluminum salt adjuvant, with a defined gE:Al3+ weight ratio range of 9:1000 to 22:1000.
Stated Advantages
Improved stability compared to live vaccine.
Optimized adjuvant ratio supports improved antibody induction/antibody responses versus live attenuated VZV vaccine.
Documented Applications
Preventing or treating varicella (chickenpox).
Preventing or treating herpes zoster.
Interested in licensing this patent?